Zhejiang Jingke Pharmaceuticals Co. Ltd. has disclosed new deuterated isoindoline compounds acting as sigma non-opioid intracellular receptor 1 (SIGMAR1) and sigma intracellular receptor 2 (TMEM97) ligands. They are described as potentially useful for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, dry macular degeneration, rheumatoid arthritis, asthma, Alzheimer's and Parkinson's disease.